“Now that enrollment is complete, we’re fully focused on completing the LOTUS trial, preparing for the data readout in mid-2026, and progressing our Phase 3 planning,” said Dr. Garry Neil, Chief Executive Officer. “This marks an important transition for Avalo as we turn our focus from enrollment to completion of the trial, guided by strong conviction in AVTX-009’s high-affinity inhibition of IL-1beta and its potential to deliver meaningful benefit for people living with hidradenitis suppurativa.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Completes Enrollment for Phase 2 LOTUS Trial
- Avalo Therapeutics completes enrollment in Phase 2 LOTUS trial
- Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study
- Oppenheimer healthcare analysts hold an analyst/industry conference call
- Avalo Therapeutics management to meet with Piper Sandler